In short
A new clinical trial is exploring the potential of NGI226 microparticles as a treatment for Achilles tendinopathy. This study aims to evaluate the safety, tolerability, and preliminary effectiveness of NGI226 when administered as a single peritendon injection. The trial compares NGI226 to a placebo in patients suffering from mid-portion Achilles tendinopathy, focusing on both local and systemic effects, as well as improvements in tendon mechanical properties.
At a glance
- Study Title
- Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy
- Condition
- Achilles Tendinopathy
- Treatment
- Single peritendon injection of NGI226 microparticles vs. placebo
- Primary Outcome
- Number of participants with adverse events and serious adverse events
- Secondary Outcome
- Changes in tendon stiffness from baseline at week 12
- Assessment Method
- Ultrasound-based shear wave elastography (SWE)
- Study Duration
- Up to 169 days (End of Study)
- Masking
- Participant and Investigator-blinded, including outcomes assessor
What is NGI226?
NGI226 is an experimental drug currently being studied for its potential in treating Achilles tendinopathy. It is formulated as microparticles (MP), which are tiny particles designed to deliver the medication effectively to the targeted area. The exact mechanism of how NGI226 works is not fully disclosed in the available information, but it is being investigated for its ability to aid in tendon regeneration.
What Condition Does NGI226 Target?
NGI226 is specifically being studied for the treatment of Achilles tendinopathy. Achilles tendinopathy is a condition that affects the Achilles tendon, which is the large tendon connecting your calf muscles to your heel bone. This condition is characterized by pain, swelling, and stiffness in the Achilles tendon, often resulting from overuse or injury. It can significantly impact a person's ability to walk, run, or participate in physical activities.
Current Clinical Trial
NGI226 is currently being evaluated in a clinical trial to assess its safety, tolerability, and preliminary efficacy in patients with Achilles tendinopathy. The study is designed as follows:
- Type of study: It is a randomized, participant and investigator-blinded, 2-arm, parallel-design, placebo-controlled study. This means that participants are randomly assigned to either receive NGI226 or a placebo, and neither the participants nor the investigators know who is receiving which treatment.
- Masking: The study is blinded, meaning that participants, care providers, investigators, and outcomes assessors are not aware of which treatment each participant is receiving. This helps to prevent bias in the results.
- Comparison: The study compares NGI226 microparticles to placebo microparticles to determine if NGI226 offers any benefits over a placebo treatment.
How is NGI226 Administered?
In the clinical trial, NGI226 is administered as a single peritendon injection. This means that the medication is injected around the tendon, specifically in the area surrounding the Achilles tendon. This method of administration is designed to deliver the medication directly to the affected area.
Safety and Efficacy Evaluation
The primary focus of the current study is to assess the safety and tolerability of NGI226. The researchers are monitoring several aspects:
- Adverse Events (AEs) and Serious Adverse Events (SAEs): These are any unintended or harmful effects that occur during the study period.
- ECG parameters: This involves monitoring the electrical activity of the heart to ensure the treatment doesn't cause any cardiac issues.
- Laboratory tests: This includes chemistry and hematology parameters, which involve analyzing blood samples for various markers of health and potential side effects.
- Urinalysis: This involves examining urine samples for any signs of adverse effects.
- Local tolerability: This refers to how well the injection site tolerates the treatment, checking for any local reactions or issues.
The study will monitor these safety aspects for up to 169 days (about 5.5 months) after the treatment.
Potential Benefits of NGI226
While the primary focus of the current study is on safety, the researchers are also looking at potential benefits of NGI226. One key aspect they're investigating is the effect of NGI226 on tendon stiffness. They will use a technique called ultrasound-based shear wave elastography (SWE) to measure changes in tendon stiffness from the start of the study to 12 weeks after treatment.
The goal is to see if NGI226 can help restore the biomechanical integrity of the Achilles tendon. In simpler terms, they're checking if the treatment can help the tendon regain its normal flexibility and strength. This could potentially lead to improvements in symptoms and function for people with Achilles tendinopathy.